clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT00352794 |
P6099 | clinical trial phase | phase II clinical trial | Q42824440 |
P17 | country | United States of America | Q30 |
P582 | end time | 2018-03-08 | |
P1050 | medical condition | chronic idiopathic myelofibrosis | Q3857106 |
P2899 | minimum age | 18 | |
P1132 | number of participants | 40 | |
P4844 | research intervention | prednisone | Q424972 |
(RS)-lenalidomide | Q425681 | ||
P6153 | research site | The University of Texas MD Anderson Cancer Center | Q1525831 |
P580 | start time | 2006-07-07 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | Evaluation of Lenalidomide (CC-5013) and Prednisone as a Therapy for Patients With Myelofibrosis (MF) |
Search more.